Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

347 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC). Andreassen CN, et al. Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18. Radiother Oncol. 2016. PMID: 27443449 Free PMC article.
Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer.
Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, Andersen LJ, Andersen E, Grau C. Mortensen HR, et al. Radiother Oncol. 2012 Apr;103(1):69-75. doi: 10.1016/j.radonc.2012.01.002. Epub 2012 Mar 5. Radiother Oncol. 2012. PMID: 22398313 Clinical Trial.
Late onset of skin toxicity induced by EGFr-inhibitors.
Eriksen JG, Overgaard M. Eriksen JG, et al. Radiother Oncol. 2009 Feb;90(2):280-1. doi: 10.1016/j.radonc.2008.10.014. Epub 2008 Nov 17. Radiother Oncol. 2009. PMID: 19010559 No abstract available.
The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study.
Hoff CM, Hansen HS, Overgaard M, Grau C, Johansen J, Bentzen J, Overgaard J. Hoff CM, et al. Radiother Oncol. 2011 Jan;98(1):28-33. doi: 10.1016/j.radonc.2010.09.024. Epub 2010 Oct 20. Radiother Oncol. 2011. PMID: 20970213 Clinical Trial.
Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol.
Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, Mouridsen HT. Blichert-Toft M, et al. Acta Oncol. 2008;47(4):672-81. doi: 10.1080/02841860801971439. Acta Oncol. 2008. PMID: 18465335 Clinical Trial.
The main objective of the present study aims at comparing the long-term efficacy of breast conserving surgery (BCS) vs. mastectomy (M) based on a randomized design. ...Looking into the type of local relapse, viz., new primaries vs. true recurrences, it appeared that new pr …
The main objective of the present study aims at comparing the long-term efficacy of breast conserving surgery (BCS) vs. mastectomy (M
The Danish national guidelines for treatment of oral squamous cell carcinoma.
Bilde A, von Buchwald C, Johansen J, Bastholt L, Sørensen JA, Marker P, Krogdahl A, Hansen HS, Specht L, Kirkegaard J, Andersen E, Bentzen J, Hjort-Sørensen C, Andersen LJ, Nielsen BA, Bundgaard T, Overgaard M, Grau C; Danish Society for Head and Neck Oncology. Bilde A, et al. Acta Oncol. 2006;45(3):294-9. doi: 10.1080/02841860600592998. Acta Oncol. 2006. PMID: 16644572
Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials.
Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Nielsen HM, et al. Radiother Oncol. 2006 May;79(2):147-55. doi: 10.1016/j.radonc.2006.04.006. Epub 2006 Apr 27. Radiother Oncol. 2006. PMID: 16647152
A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine.
Bentzen JKD, Kristensen CA, Overgaard M, Rytter C, Jensen K, Hansen HS. Bentzen JKD, et al. Front Oncol. 2018 Jun 29;8:243. doi: 10.3389/fonc.2018.00243. eCollection 2018. Front Oncol. 2018. PMID: 30009154 Free PMC article.
The treatment consisted of paclitaxel 175 mg/m(2), once every third week and capecitabine 825 mg/m(2) p.o. b.i.d for 2 weeks. ...
The treatment consisted of paclitaxel 175 mg/m(2), once every third week and capecitabine 825 mg/m(2) p.o. b.i.d for 2 weeks. …
DAHANCA 9 - a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC).
Evensen JF, Sand Hansen H, Overgaard M, Johansen J, Andersen LJ, Overgaard J. Evensen JF, et al. Acta Oncol. 2019 Oct;58(10):1502-1505. doi: 10.1080/0284186X.2019.1629012. Epub 2019 Jul 8. Acta Oncol. 2019. PMID: 31282236 Clinical Trial. No abstract available.
347 results
Jump to page
Feedback